Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DFF332 + Spartalizumab + Taminadenant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DFF332 | DFF 332|DFF-332 | HIF2A Inhibitor 6 | DFF332 inhibits HIF-2alpha and blocks its DNA binding, which may lead to downregulation of HIF-2alpha target genes involved in tumor cell growth and survival (NCI Drug Dictionary). | |
Spartalizumab | PDR001|PDR-001 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 | Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633). | |
Taminadenant | NIR178|PBF-509 | Adenosine Targeting 24 | Taminadenant binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04895748 | Phase I | DFF332 + Spartalizumab + Taminadenant DFF332 + Everolimus DFF332 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | Active, not recruiting | USA | ITA | FRA | ESP | CZE | 2 |